307 related articles for article (PubMed ID: 20067773)
1. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
2. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.
Zhang X; Sun Y; Pireddu R; Yang H; Urlam MK; Lawrence HR; Guida WC; Lawrence NJ; Sebti SM
Cancer Res; 2013 Mar; 73(6):1922-33. PubMed ID: 23322008
[TBL] [Abstract][Full Text] [Related]
3. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
4. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
5. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects.
Siddiquee KA; Gunning PT; Glenn M; Katt WP; Zhang S; Schrock C; Sebti SM; Jove R; Hamilton AD; Turkson J
ACS Chem Biol; 2007 Dec; 2(12):787-98. PubMed ID: 18154266
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
Jaganathan S; Yue P; Turkson J
J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.
Ball DP; Lewis AM; Williams D; Resetca D; Wilson DJ; Gunning PT
Oncotarget; 2016 Apr; 7(15):20669-79. PubMed ID: 26942696
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis.
Sen N; Che X; Rajamani J; Zerboni L; Sung P; Ptacek J; Arvin AM
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):600-5. PubMed ID: 22190485
[TBL] [Abstract][Full Text] [Related]
10. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
[TBL] [Abstract][Full Text] [Related]
11. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
[TBL] [Abstract][Full Text] [Related]
12. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Wang Z; Li J; Xiao W; Long J; Zhang H
Lab Invest; 2018 Dec; 98(12):1600-1613. PubMed ID: 30206312
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.
Fletcher S; Page BD; Zhang X; Yue P; Li ZH; Sharmeen S; Singh J; Zhao W; Schimmer AD; Trudel S; Turkson J; Gunning PT
ChemMedChem; 2011 Aug; 6(8):1459-70. PubMed ID: 21618433
[TBL] [Abstract][Full Text] [Related]
14. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.
Chen H; Bian A; Yang LF; Yin X; Wang J; Ti C; Miao Y; Peng S; Xu S; Liu M; Qiu WW; Yi Z
Oncogene; 2021 Feb; 40(8):1440-1457. PubMed ID: 33420372
[TBL] [Abstract][Full Text] [Related]
15. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne EJ; Klostergaard J; Mandal PK; Liao WS; Lu Z; Gao F; Bast RC; Robertson FM; McMurray JS
J Exp Ther Oncol; 2012; 10(2):155-62. PubMed ID: 23350355
[TBL] [Abstract][Full Text] [Related]
16. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.
Yue P; Lopez-Tapia F; Paladino D; Li Y; Chen CH; Namanja AT; Hilliard T; Chen Y; Tius MA; Turkson J
Cancer Res; 2016 Feb; 76(3):652-63. PubMed ID: 26088127
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein.
Kotha A; Sekharam M; Cilenti L; Siddiquee K; Khaled A; Zervos AS; Carter B; Turkson J; Jove R
Mol Cancer Ther; 2006 Mar; 5(3):621-9. PubMed ID: 16546976
[TBL] [Abstract][Full Text] [Related]
18. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
[TBL] [Abstract][Full Text] [Related]
19. Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.
Kumar G; Goldberg SN; Gourevitch S; Levchenko T; Torchilin V; Galun E; Ahmed M
Radiology; 2018 Feb; 286(2):524-536. PubMed ID: 28880787
[TBL] [Abstract][Full Text] [Related]
20. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
